Mirza, M R, Bjorge, L, Marme, F, Christensen, R D, Gil-Martin, M, Auranen, A, Ataseven, B, Rubio, M J, Salutari, V, Lund, B, Runnebaum, I, Redondo, A, Lindemann, K, Trillsch, F, Barretina Ginesta, M P, Roed, H, Lohndorf, J, Nyvang, G-B & Sehouli, J 2020, ' A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial ', Annals of Oncology, vol. 31, no. Suppl. 4, LBA28, pp. S1160 . https://doi.org/10.1016/j.annonc.2020.08.2258
Mirza, M R, Bjørge, L, Marmé, F, Christensen, R D, Gil-Martin, M, Auranen, A, Ataseven, B, Rubio, M J, Salutari, V, Lund, B, Runnebaum, I, Redondo, A, Lindemann, K, Trillsch, F, Ginesta, M P B, Roed, H, Løhndorf, J, Nyvang, G-B & Sehouli, J 2020, ' A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC) : NSGO-PALEO / ENGOT-EN3 trial ', Annals of Oncology, vol. 31, no. Suppl. 4, LBA28, pp. S1160 . https://doi.org/10.1016/j.annonc.2020.08.2258